Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists

@article{Albanese2003DihydroergocriptineIP,
  title={Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists},
  author={Alberto Albanese and Carlo Colosimo},
  journal={Acta Neurologica Scandinavica},
  year={2003},
  volume={107}
}
The present paper reviews clinical studies on the use of dihydroergocriptine (DHEC), an ergot derivative with dopamine agonist activity, for the treatment of Parkinson's disease. This compound is a hydrogenated ergot derivative structurally quite similar to bromocriptine, from which it differs because of the hydrogenation in C9–C10 and the lack of bromine in C2. DHEC has a potent D2‐like receptor agonist and a partial D1‐like receptor agonist activity; because of this biochemical profile, it… 
View on Wiley
albanese.biz
14 Citations
Highly Influential Citations
1
Background Citations
5
Results Citations
1

14 Citations

Citation Type

Citation Type

Dopamine Agonists in Parkinson Disease : Special Focus on Pramipexole
TLDR
In addition to abating the core symptoms of PD and delaying the onset of motor complications, the dopamine agonist pramipexole has been shown to ameliorate tremor and depressive symptoms in clinical practice.
Synergistic effect of α-dihydroergocryptine and L-dopa or dopamine on dopaminergic neurons in primary culture
TLDR
The novel finding that the combination of a dopamine (DA) agonist, α-dihydroergocryptine (DHEC), with L-dopa or DA exerts a synergistic stimulatory effect on dopaminergic neurons in primary culture, while each substance alone had no or less effect is described.
Dopamine receptor agonists in the therapy of Parkinson’s disease
TLDR
It is concluded that there is little unequivocal evidence to suggest that any of the major dopamine receptor agonists should be invariably preferred in the therapy of Parkinson’s disease; their application must be based on the needs and responses of individual patients.
Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinson’s Disease
TLDR
Dopamine receptor agonists are indicated for the symptomatic treatment of early, moderate or advanced Parkinson’s disease as well as for the reduction of levodopa-related motor complications and other issues, including the efficacy of dopamine agonists for the treatment of non-motor symptoms, remain under evaluation.
Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease
  • D. Nyholm
  • Medicine, Biology
    Clinical pharmacokinetics
  • 2006
TLDR
In general, initial dopamine receptor agonist monotherapy is associated with poorer motor performance and lower incidence of motor complications compared with levodopa, and CDS can be approached by optimising the use of dopaminergic drugs based on pharmacokinetic data.
Group III metabotropic glutamate receptors as potential targets in the treatment of Parkinson's disease
TLDR
Intranigral injections of L-SOP, L-AP4, PHCCC and (S)-3,4-DCPG were shown to reverse reserpine-induced akinesia, suggesting activation of mGlu4 and mGiu8 may underlie this effect, and data support the antiparkinsonian potential of group III mGLU.
Parkinson Disease in Primary Practice : Keys to Diagnosis and Management
TLDR
This article is designed to provide primary clinicians with clinical criteria to better distinguish PD from other conditions with parkinsonian features and to present an evidencebased review of PD treatment.
Review of the available evidence on Oral Dopamine Agonists For Parkinson ’ s Disease
TLDR
Recommendations on the use of DAs from international guidelines on PD and grading systems adopted in the included guidelines Update of the Cochrane systematic review of dopamine agonist therapy in early Parkinson's disease.
Pharmacotherapy and Treatment of Parkinson's Disease
TLDR
This chapter reviews the current practice of treatment for Parkinson's disease, with special emphasis on the management of treatment complications and non-motor manifestations of the disease.
Current and future therapeutic approaches in progressive supranuclear palsy.
...
1
2
...

References

SHOWING 1-10 OF 55 REFERENCES
Dihydroergocryptine in the treatment of Parkinson's disease: a six months' double-blind clinical trial.
TLDR
The authors demonstrate the efficacy and the good tolerability of DEK as a new DA agonist drug that can be added to LD in the treatment of parkinsonian patients.
Clinical usefulness of apomorphine in movement disorders.
TLDR
The available data suggest apomorphine (in conjunction with domperidone) as a first-choice treatment for the neuroleptic malignant syndrome and the temporary replacement of levodopa (e.g., after gastrointestinal surgery).
BROMOCRIPTINE ASSOCIATED WITH A PERIPHERAL DOPAMINE BLOCKING AGENT IN TREATMENT OF PARKINSON'S DISEASE
Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease
TLDR
It is indicated that pramipexole is safe and effective in the treatment of early Parkinson's disease and significantly reduced the severity of PD symptoms and signs compared with placebo.
Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease
TLDR
It is concluded that pramipexole-treated patients with advanced PD improved significantly more than placebo for both primary end points and in regard to comparison of the Global Clinical Assessment of Efficacy between active treatment groups, there was a trend to significance in favor of pramipingxole.
Alpha‐dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study
TLDR
Alpha‐dihydroergocryptine effect seems to be superior to that of lisuride both in terms of reduction of l‐dopa therapy long term motor complications (UPDRS part IV) as well as in Terms of the incidence and severity of adverse events.
A Rationale for Dopamine Agonists as Primary Therapy for Parkinson’s Disease
  • C. Olanow
  • Psychology, Medicine
    Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
  • 1992
TLDR
In this way symptomatic control is not compromised on theoretical grounds, but the cumulative levodopa dose is minimized in an effort to reduce the likelihood of free radical formation with their potential adverse consequences on disease progression.
Treatment of restless legs syndrome with the dopamine agonist alpha‐dihydroergocryptine
TLDR
An open pilot study with the dopamine agonist α‐dihydroergocryptine (DHEC) was conducted in 16 patients with idiopathic restless legs syndrome, suggesting a role for DHEC in the treatment of RLS.
Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease
TLDR
The results of the present study suggest that changes in central dopaminergic mechanisms contributing to motor complications in advanced Parkinson's disease can be modified by procedures that provide continuous dopamine replacement.
Alpha‐dihydroergocryptine in the treatment of de novo parkinsonian patients: results ofa multicentre, randomized, double‐blind, placebo‐controlled study
TLDR
The results indicate that α‐dihydroergocryptine is safe and effective in improving symptoms of de novo parkinsonian patients.
...
1
2
3
4
5
...